Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
NEW YORK& MAINZ, Germany--(BUSINESS WIRE) September 26, 2022 -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA)...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Children | Clinical Trials | Emergency Medicine | Food and Drug Administration (FDA) | Germany Health | Pfizer | Pharmaceuticals | Vaccines